Innovation and Execution to Drive Above-Market Growth for Qiagen
Qiagen is a leading player in the life sciences industry, with core strengths in sample preparation and analytics and additional activities in clinical diagnostics.
Qiagen NV QGEN
Bulls Say, Bears Say
Bulls
Qiagen is active in multiple potentially fast-growing end markets like dPCR and bioinformatics and has product launches coming up, supporting strong growth over the long run.
Bears
Qiagen will continue to face intense competition in its heavily invested diagnostics markets, which could harm financial returns.
News
-
10x Genomics Wins Patent Infringement Verdict Against Parse Biosciences
-
QIAGEN Launches QIAsymphony Connect for Automated Clinical Nucleic Acid Extraction
-
QIAGEN Appoints Jonathan M. Pratt as Chief Executive Officer
-
Qiagen Wins FDA Clearance for Bloodstream Infection Test
-
QIAGEN Receives U.S. FDA Clearance for First QIAstat-Dx Bloodstream Infection Panel
-
QIAGEN Exceeds Q2 2026 Outlook as Pillars Deliver Solid Sales Growth; Reaffirms Full-Year Outlook
-
QIAGEN Highlights Molecular Testing Solutions Supporting Response to Growing U.S. Cyclospora Outbreak
-
QIAGEN N.V. to Release Results for Q2 2026 and Hold Webcast
Articles & Videos
Trading Information
- Previous Close Price
- $43.86
- Day Range
- $42.79–43.66
- 52-Week Range
- $32.53–57.82
- Bid/Ask
- $40.00 / $45.50
- Shares Outstanding
- 206.50M
- Market Cap
- $8.98B
- Volume/Avg
- 2M / 3M
Key Statistics
- Price/Earnings (Normalized)
- 17.94
- Price/Sales
- 4.31
- Dividend Yield (Trailing)
- 0.81%
- Dividend Yield (Forward)
- 0.81%
- Dividend Payment Schedule
- Jul
- Total Yield
- 7.18%
Company Profile
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables, with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by Europe, the Middle East, and Africa (33%) and Asia-Pacific (15%).
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Stock Style Box
- Small Core
- Total Number of Employees
- 5,500
- Website
- https://www.qiagen.com
Competitors
Valuation
|
Metric
|
QGEN
|
ILMN
|
DHR
|
|---|---|---|---|
Price/Earnings (Normalized) | 17.94 | 42.37 | 25.57 |
Price/Book Value | 2.67 | 11.61 | 2.78 |
Price/Sales | 4.31 | 7.48 | 5.88 |
Price/Cash Flow | 13.45 | 25.91 | 20.60 |
Price/Earnings
QGEN
ILMN
DHR
Financial Strength
|
Metric
|
QGEN
|
ILMN
|
DHR
|
|---|---|---|---|
Quick Ratio | 2.04 | 1.22 | 1.03 |
Current Ratio | 2.85 | 1.80 | 1.65 |
Interest Coverage | 11.32 | 10.96 | 16.95 |
Quick Ratio
QGEN
ILMN
DHR
Profitability
|
Metric
|
QGEN
|
ILMN
|
DHR
|
|---|---|---|---|
Return on Assets (Normalized) | 8.94% | 6.73% | 5.34% |
Return on Equity (Normalized) | 15.39% | 16.79% | 8.59% |
Return on Invested Capital (Normalized) | 10.05% | 9.37% | 6.45% |
Return on Assets
QGEN
ILMN
DHR
Diagnostics & Research Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Thermo Fisher Scientific Inc
TMO
| LOCK|<dVbKly | LOCK|sGG | $227B | |||
| Danaher Corp
DHR
| LOCK|tjlHG$W# | LOCK|&&K | $146B | |||
| IQVIA Holdings Inc
IQV
| LOCK|<n!Gnb< | LOCK|S<q? | $44B | |||
| Agilent Technologies Inc
A
| LOCK|Fcn@P$N | LOCK|Lf% | $43B | |||
| IDEXX Laboratories Inc
IDXX
| LOCK|#$fbC^! | LOCK|?b | $42B | |||
| Waters Corp
WAT
| LOCK|fQ#K#N | LOCK|?@> | $40B | |||
| Illumina Inc
ILMN
| LOCK|!@$n^X | LOCK|pG<% | $33B | |||
| Mettler-Toledo International Inc
MTD
| LOCK|?Jtb!%X | LOCK|Krw&@ | $27B | |||
| Labcorp Holdings Inc
LH
| LOCK|cxr>&?g | LOCK|vKj< | $27B | |||
| Quest Diagnostics Inc
DGX
| LOCK|!Jn#nck | LOCK|NhZMR | $26B |
United States